MediWound (NASDAQ:MDWD) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

MediWound (NASDAQ:MDWD) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09, FiscalAI reports. The firm had revenue of $1.87 million for the quarter, compared to analyst estimates of $2.09 million. MediWound had a negative net margin of 140.80% and a negative return on equity of 70.55%.

Here are the key takeaways from MediWound’s conference call:

• EscharEx phase 3 VALUE trial is actively enrolling toward a 216?patient target across ~40 U.S./EU sites with a pre?specified interim assessment and expected enrollment completion by year?end 2026, and the company plans a phase 2 diabetic foot ulcer study plus an investigator pressure?ulcer study in H2 2026 with multiple industry collaborators (e.g., B. Braun).
• The expanded NexoBrid manufacturing facility is operational and boosts production capacity sixfold, with commercial release pending regulatory clearances expected in 2026 and management prioritizing support for burn?center adoption and national stockpiling/military preparedness.
• 2025 revenue declined to $17.0M (Q4 $1.9M) and operating/adjusted EBITDA losses widened as R&D rose to $14.3M to fund EscharEx, with the shortfall driven primarily by a U.S. government shutdown and lower product sales to Vericel.
• The balance sheet was strengthened to $53.6M in cash following a $30M registered direct offering and warrant exercises, and management reaffirmed multi?year revenue guidance ($24–26M in 2026; $32–35M in 2027; $50–55M in 2028), while noting these forecasts assume BARDA/DoD support.

MediWound Stock Down 2.4%

Shares of NASDAQ:MDWD traded down $0.42 during trading on Friday, reaching $17.03. The stock had a trading volume of 80,345 shares, compared to its average volume of 77,207. The stock has a fifty day simple moving average of $17.70 and a two-hundred day simple moving average of $17.86. MediWound has a 52 week low of $14.14 and a 52 week high of $22.50. The firm has a market capitalization of $218.15 million, a price-to-earnings ratio of -8.11 and a beta of 0.13.

Key MediWound News

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: 2026–2027 revenue guidance raised/outlined above street expectations — the company issued a 2026 revenue target of $24M–$26M (vs. consensus ~$22.6M) and 2027 guidance of $32M–$35M (vs. consensus ~$25.8M), suggesting material top?line growth ahead if execution stays on track. MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs
• Positive Sentiment: Clinical and manufacturing progress: EscharEx Phase III (VALUE) is advancing as planned, NexoBrid manufacturing capacity has been expanded and is operational, and management expects regulatory approvals in 2026 — these operational milestones de?risk near?term commercialization upside. The company also finished the year with roughly $54M in cash. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Company filed its Form 20?F for fiscal 2025 (routine disclosure). This is standard compliance and provides more detail for investors but is not a catalyst by itself. MediWound Files Annual Report on Form 20-F
• Neutral Sentiment: Earnings call transcript and details are available for investors who want management color on 2026 assumptions and the EscharEx program; use this to judge credibility of guidance and timing of approvals. MediWound (MDWD) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed expectations — reported quarterly revenue of $1.87M vs. analysts’ ~$2.09M estimate, highlighting a small current revenue base and near?term sensitivity to sales execution. MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Still unprofitable with wide negative margins — Q4 GAAP loss of $0.56/sh (a smaller loss than expected), but the company reported negative net margin and return on equity, underscoring continued cash burn risk until commercial scale or regulatory approvals materialize. That combination helps explain downward pressure on the stock today. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Wall Street Zen cut shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Finally, Zacks Research upgraded MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MediWound currently has a consensus rating of “Hold” and a consensus target price of $31.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MDWD. Sphera Funds Management LTD. raised its holdings in MediWound by 24.3% in the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock worth $4,252,000 after acquiring an additional 45,077 shares during the period. Kotler Kevin bought a new stake in MediWound during the fourth quarter valued at about $6,225,000. Russell Investments Group Ltd. grew its position in shares of MediWound by 45.1% in the fourth quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,135 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of MediWound in the fourth quarter valued at about $297,000. Finally, Barclays PLC increased its stake in shares of MediWound by 32.5% in the fourth quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 3,747 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.